Two Sigma Advisers
DNLI icon

Two Sigma Advisers’s Denali Therapeutics DNLI Stock Holding History

Two Sigma Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-154,800
Closed -$2.56M – 609
2025
Q4 		$2.56M Buy
154,800
+64,800
+72% +$1.09M 0.01% 1083
2025
Q3 		$1.31M Buy
90,000
+62,400
+226% +$897K ﹤0.01% 1331
2025
Q2 		$386K Sell
27,600
-7,700
-22% -$108K ﹤0.01% 1863
2025
Q1 		$480K Buy
35,300
+20,200
+134% +$387K ﹤0.01% 1796
2024
Q4 		$308K Buy
+15,100
New +$387K ﹤0.01% 1968
2024
Q2 		– Sell
-21,900
Closed -$449K – 2500
2024
Q1 		$449K Buy
+21,900
New +$412K ﹤0.01% 1915
2023
Q3 		– Sell
-26,400
Closed -$779K – 2433
2023
Q2 		$779K Sell
26,400
-91,500
-78% -$2.57M ﹤0.01% 1632
2023
Q1 		$2.72M Sell
117,900
-33,900
-22% -$933K 0.01% 1109
2022
Q4 		$4.22M Sell
151,800
-32,000
-17% -$952K 0.01% 851
2022
Q3 		$5.64M Buy
183,800
+23,300
+15% +$758K 0.02% 680
2022
Q2 		$4.72M Sell
160,500
-11,700
-7% -$306K 0.01% 802
2022
Q1 		$5.54M Sell
172,200
-97,400
-36% -$3.35M 0.01% 760
2021
Q4 		$12M Sell
269,600
-151,500
-36% -$7.18M 0.03% 447
2021
Q3 		$21.2M Sell
421,100
-43,000
-9% -$2.42M 0.06% 303
2021
Q2 		$36.4M Buy
464,100
+12,800
+3% +$792K 0.1% 219
2021
Q1 		$25.8M Buy
451,300
+190,200
+73% +$12.7M 0.07% 295
2020
Q4 		$21.9M Buy
261,100
+200,700
+332% +$12.1M 0.06% 329
2020
Q3 		$2.16M Buy
60,400
+48,200
+395% +$1.45M 0.01% 1127
2020
Q2 		$295K Buy
+12,200
New +$287K ﹤0.01% 2123

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Advisers's DNLI Position: Q1 2026 in Review

Two Sigma Advisers sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 154,800 shares — an estimated $2.56M sold.

Two Sigma Advisers first reported a position in DNLI in Q2 2020 and held it in 19 quarters. The position peaked at $36.4M in Q2 2021. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Two Sigma Advisers reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 154,800 Denali Therapeutics shares in Q1 2026, an estimated $2.56M.
  • Two Sigma Advisers first reported a position in Denali Therapeutics in Q2 2020 and held it in 19 quarters.
  • Two Sigma Advisers's Denali Therapeutics position peaked at $36.4M in Q2 2021.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.